Want to see TSE:CSCI full AI Analyst Report?
Top Page
COSCIENS Biopharma
(TSX:CSCI)
Select Model
Select Model
Rating:46Neutral
Price Target:
C$7.50
▲(0.00% Upside)
Action:Reiterated
Date:08/26/26
Overall score reflects financial stabilization but continued fundamental risk: narrowing losses and improved margins are positives, yet persistent unprofitability and ongoing negative free cash flow weigh heavily. Technicals add pressure with the stock below key moving averages and negative MACD, while valuation is hard to support given a negative P/E and no dividend yield data.
Positive Factors
Improving margins and narrowing losses
Improved gross margin and sharply lower losses indicate operating stabilization, while revenue has returned to modest growth. If production efficiencies and sales volumes persist, the business could build a better earnings base over the next several quarters.
Negative Factors
Persistent unprofitability
Losses have narrowed but remain substantial relative to revenue, showing that the business has not yet demonstrated a durable path to profitability. Continued operating losses could constrain investment, financing flexibility and shareholder returns.
Read all positive and negative factors
Positive Factors
Negative Factors
Improving margins and narrowing losses
Improved gross margin and sharply lower losses indicate operating stabilization, while revenue has returned to modest growth. If production efficiencies and sales volumes persist, the business could build a better earnings base over the next several quarters.
Read all positive factors
COSCIENS Biopharma (CSCI) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$7.60M
Dividend YieldN/A
Average Volume (3M)727.00
Price to Earnings (P/E)―
Beta (1Y)2.70
Revenue Growth-13.00%
EPS Growth75.31%
CountryCA
Employees28
SectorHealthcare
Sector Strength45
IndustryMedical - Pharmaceuticals
Share Statistics
EPS (TTM)-13.03
Shares Outstanding996,394
10 Day Avg. Volume647
30 Day Avg. Volume727
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.57
Price to Sales (P/S)0.29
P/FCF Ratio-0.23
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
COSCIENS Biopharma Business Overview & Revenue Model
Company Description
COSCIENS Biopharma Inc., a life science company, develops and commercializes products for the cosmeceutical, nutraceutical and pharmaceutical markets in the United States, Germany, the United Kingdom, and internationally. It operates through Activ...
COSCIENS Biopharma Financial Statement Overview
Summary
Income Statement
24
Negative
Balance Sheet
62
Positive
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2025 | Mar 2025 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 8.18M | 7.63M | 9.59M | 4.50M | 14.57M | 5.26M |
| Gross Profit | 3.70M | 2.69M | 4.73M | 4.28M | 8.56M | 5.17M |
| EBITDA | -3.55M | -9.41M | -13.49M | -17.99M | -15.36M | 2.85M |
| Net Income | -4.74M | -10.54M | -15.31M | -3.55M | 3.24M | 2.64M |
Balance Sheet | ||||||
| Total Assets | 18.82M | 21.39M | 35.07M | 37.02M | 56.03M | 80.10M |
| Cash, Cash Equivalents and Short-Term Investments | 5.27M | 7.29M | 16.39M | 34.02M | 50.61M | 65.30M |
| Total Debt | 1.95M | 2.15M | 2.31M | 3.39M | 3.86M | 4.16M |
| Total Liabilities | 4.00M | 17.56M | 21.91M | 18.82M | 20.25M | 27.12M |
| Stockholders Equity | 14.82M | 3.84M | 13.16M | 18.20M | 35.78M | 52.99M |
Cash Flow | ||||||
| Free Cash Flow | -3.74M | -9.34M | -15.73M | -17.14M | -13.69M | -9.22M |
| Operating Cash Flow | -3.69M | -8.62M | -14.57M | -2.62M | -13.68M | -8.58M |
| Investing Cash Flow | -8.29K | -466.02K | 25.08M | 528.00K | -12.00K | -658.00K |
| Financing Cash Flow | -235.05K | -414.12K | -588.00K | -151.00K | -118.00K | 51.04M |
COSCIENS Biopharma Technical Analysis
Neutral
7.50
Price Trends
8.17
Negative
8.17
Negative
7.98
Negative
Market Momentum
-0.13
Negative
50.18
Neutral
80.21
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:CSCI, the sentiment is Neutral. The current price of 7.5 is below the 20-day moving average (MA) of 7.55, below the 50-day MA of 8.17, and below the 200-day MA of 7.98, indicating a neutral trend. The MACD of -0.13 indicates Negative momentum. The RSI at 50.18 is Neutral, neither overbought nor oversold. The STOCH value of 80.21 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for TSE:CSCI.
COSCIENS Biopharma Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | C$25.67M | -15.77 | -72.15% | ― | 224.46% | 28.37% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | C$48.57M | -24.00 | 19.88% | ― | ― | 15.07% | |
46 Neutral | C$7.60M | -0.44 | -48.52% | ― | -13.00% | 75.31% | |
46 Neutral | C$9.45M | -5.62 | 39.05% | ― | ― | 25.70% | |
45 Neutral | C$7.70M | -50.00 | -10.61% | ― | 56.41% | 91.30% | |
39 Underperform | C$5.01M | -4.55 | -155.46% | ― | ― | 26.95% |
* Healthcare Sector Average
TSE:CSCI
COSCIENS Biopharma
7.63
-2.90
-27.59%
TSE:BETR
BetterLife Pharma
0.30
0.21
252.94%
TSE:PHRM
PharmaTher Holdings Ltd
0.06
-0.32
-85.33%
TSE:GLOW
Glow LifeTech
0.04
-0.02
-27.27%
TSE:MRVL
Marvel Biosciences Corp
0.15
-0.10
-40.00%
TSE:MDMA
PharmAla Biotech Holdings, Inc.
0.24
0.12
113.64%
COSCIENS Biopharma Corporate Events
Business Operations and StrategyFinancial DisclosuresRegulatory Filings and Compliance
COSCIENS Biopharma Swings to First-Half Profit and Cuts Costs as It Exits SEC Reporting
Positive
Aug 11, 2026
COSCIENS Biopharma reported a sharply narrowed net loss of $0.2 million for Q2 2026, compared with a $2.7 million loss a year earlier, on revenue that rose to $3.1 million from $2.4 million. For the first half of 2026, the company swung to net inc...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.